

SUMMARY OF PRODUCT CHARACTERISTICS

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Doxycare Flavour 200 mg Tablets for Cats and Dogs

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each tablet contains:

Active substance:

Doxycycline 200 mg
(equivalent to 239.40 mg of doxycycline hyclate)

Excipients:

For the full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

Tablet

Yellowish, round and convex tablet with a cross-shaped break line on one side.

Tablets can be divided into 2 or 4 equal parts.

4. CLINICAL PARTICULARS

4.1 Target species

Cats and dogs

4.2 Indications for use, specifying the target species

Dogs

For the treatment of respiratory tract infections including rhinitis, tonsillitis and bronchopneumonia caused by *Bordetella bronchiseptica*, and *Pasteurella* spp. susceptible to doxycycline.

For the treatment of canine ehrlichiosis caused by *Ehrlichia canis*.

Cats

For the treatment of respiratory tract infections including rhinitis, tonsillitis and bronchopneumonia caused by *Bordetella bronchiseptica*, and *Pasteurella* spp. susceptible to doxycycline.

4.3 Contraindications

Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

Do not use in animals with renal or hepatic insufficiency.

Do not use in animals with diseases associated with vomiting or dysphagia (see also section 4.6).

Do not use in animals with known photosensitivity (see also section 4.6).

Do not use in puppies and kittens before completion of teeth enamel formation.

4.4 Special warnings for each target species

Ehrlichia canis infection: treatment should be initiated at the onset of clinical signs. Complete eradication of the pathogen is not always achieved, but treatment for 28 days generally leads to a resolution of the clinical signs and a reduction of the bacterial load. A longer duration of treatment, based on a benefit/risk assessment by the responsible veterinarian, may be required particularly in severe or chronic ehrlichiosis. All treated patients should be regularly monitored, even after clinical cure.

4.5 Special precautions for use

Special precautions for use in animals

Use of the veterinary medicinal product should be based on identification and susceptibility testing of the target pathogens. If this is not possible, therapy should be based on epidemiological information and knowledge of susceptibility of the target pathogens at local/regional level.

Use of the veterinary medicinal product deviating from the instructions given in the SPC may increase the prevalence of bacteria resistant to doxycycline and may decrease the effectiveness of treatment with other tetracyclines, due to the potential for cross-resistance. Use of the veterinary medicinal product should be in accordance with official, national and regional antimicrobial policies.

Tablets should be administered with food in order to avoid vomiting and to reduce the likelihood of oesophageal irritation.

The product should be administered with caution to young animals, since tetracyclines as a class may cause permanent discolouration of the teeth, when administered during tooth development. However, human literature indicates that doxycycline is less likely than other tetracyclines to cause these abnormalities, due to its reduced ability to chelate calcium.

Special precautions to be taken by the person administering the veterinary medicinal product to animals

People with known hypersensitivity to doxycycline or other tetracyclines should avoid contact with the veterinary medicinal product and personal protective equipment consisting of gloves should be worn when handling the veterinary medicinal product. In case of skin irritation, seek medical advice immediately and show the package leaflet or the label to the physician.

Accidental ingestion, especially by children, may cause adverse reactions such as emesis.

To avoid accidental ingestion, blisters should be inserted back into the outer packaging and kept in a safe place. In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.

4.6 Adverse reactions (frequency and seriousness)

Gastrointestinal as adverse reactions including vomiting, nausea, salivation, oesophageal and diarrhoea have been reported very rarely in spontaneous reports. Photosensitivity and photodermatitis can occur following tetracycline therapy, after exposure to intense sunlight or ultraviolet light (See also section 4.3).

Use of tetracycline during the period of tooth development may lead to tooth discolouration.

The frequency of adverse reactions is defined using the following convention:

- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).

4.7 Use during pregnancy, lactation or lay

Laboratory studies in rats or rabbits have not produced any evidence of teratogenic or embryotoxic effects of doxycycline.

However, as there is no information available in the target species, use is not recommended during pregnancy.

Use only according to the benefit-risk assessment by the responsible veterinarian.

4.8 Interaction with other medicinal products and other forms of interaction

Doxycycline should not be used concurrently with other antibiotics especially bactericidal drugs such as the β -lactams. Cross-resistance to tetracyclines can occur.

The half-life of doxycycline is reduced by concurrent administration of barbiturates or phenytoin and carbamazepine.

Dosage adjustments may be necessary in subjects under anticoagulant therapy, as tetracyclines depress the plasma activity of prothrombin.

Simultaneous administration of oral absorbents, antacids and preparations including multivalent cations should be avoided as they reduce doxycycline availability.

4.9 Amounts to be administered and administration route

For oral use.

The dosage is 10 mg doxycycline per kilogram of bodyweight per day.

To ensure a correct dosage, bodyweight of the animals should be determined as accurately as possible to avoid overdosing or underdosing. In order to adjust the dosage, the tablets can be divided into 2 or 4 equal parts. Place the tablet on a flat surface, with its scored side facing up and the convex (rounded) side facing the surface. The dosage can be divided into two daily administrations. The duration of treatment might be adapted depending on the clinical response, after benefit/risk assessment by the veterinarian.

Disease	Dosage regimen	Duration of treatment
Respiratory tract infection	10 mg/kg per day	5-10 days
Canine ehrlichiosis	10 mg/kg per day	28 days

Halves: press down with your thumbs or fingers on both sides of the tablet.
Quarters: press down with your thumb or finger in the middle of the tablet.

4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary

Vomiting may occur in dogs with 5 times the recommended dose. Increased levels of ALT, GGT, ALP and total bilirubin were reported in dogs at 5-fold overdose.

4.11 Withdrawal period(s)

Not applicable.

5. PHARMACOLOGICAL PROPERTIES

Pharmacotherapeutic group: Antibacterials for systemic use, Tetracyclines
ATC vet code: QJ01AA02

5.1 Pharmacodynamic properties

Doxycycline is a broad-spectrum tetracycline-class antibiotic active against a large number of gram positive and gram negative bacteria including both aerobic and anaerobic species.

Doxycycline inhibits bacterial protein synthesis by binding to the 30-S ribosomal subunits. This interferes with binding of aminoacyl-tRNA to the acceptor site on the mRNA ribosome complex and prevents coupling of amino acids to the elongating peptide chains; doxycycline has a predominantly bacteriostatic activity.

The penetration of doxycycline into the bacterial cell takes place by both active transport and passive diffusion.

The main mechanisms of acquired resistance to tetracycline class antibiotics include active efflux and ribosomal protection. A third mechanism is enzymatic degradation. The genes mediating resistance may be carried on plasmids or transposons, as for example, *tet(M)*, *tet(O)*, and *tet(B)* that can be found in both gram-positive and gram-negative organisms including clinical isolates.

Cross-resistance to other tetracyclines is common but depends on the mechanism conferring resistance. Due to the greater liposolubility and greater ability to pass through cell membranes (in comparison to tetracycline), doxycycline retains a certain degree of efficacy against microorganisms with acquired resistance to tetracyclines via efflux pumps. However, resistance mediated by ribosomal protection proteins confer cross-resistance to doxycycline.

The following MIC values for the targeted bacteria were collected between 2017 and 2018 as a part of ongoing European surveillance studies:

Bacterial pathogen	Origin (number of strains tested)	MIC ₅₀ (µg/ml)	MIC ₉₀ (µg/ml)
<i>Bordetella bronchiseptica</i>	Dog – respiratory tract (38)	0.12	0.5
<i>Bordetella bronchiseptica</i>	Cat – respiratory tract (11)	0.12	0.12
<i>Pasteurella</i> spp.	Dog – respiratory tract (27)	0.12	0.25
<i>Pasteurella</i> spp.	Cat– respiratory tract (77)	0.12	0.25

Antibiotic susceptibility data for *Ehrlichia canis* are limited.

5.2 Pharmacokinetic particulars

Absorption

After oral administration, the bioavailability of doxycycline is approximately 45% in dogs and cats. Peak concentrations of 1.4 µg/ml (dogs) and 4.3 µg/ml (cats) are reached within 3 hours after oral administration, supporting that doxycycline is rapidly absorbed from the gastro-intestinal tract.

Distribution

Doxycycline is broadly distributed throughout the organism due to its physicochemical characteristics, as it is highly liposoluble. Protein binding in dogs is reported as 91.75 % ± 0.63 and 91.4% in the literature. In cats a publication reports a protein binding of 98.35% (+/-0.24).

The tissue concentrations, with the exception of the skin, are generally higher than the plasma levels, including the excretion organs (liver, kidney and intestines) and for the lungs.

Elimination

After a single administration, the half-life elimination (T_{1/2}) is 8.37 hours in cats. Excretion occurs in an unchanged active form (90%) via the faeces (approximately 75%), via the urine (approximately 25%) and less than 5% via the bile ducts.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Sodium starch glycolate (type A)
Cellulose microcrystalline
Yeast extract
Magnesium stearate

6.2 Major incompatibilities

Not applicable.

6.3 Shelf life

Shelf-life of the veterinary medicinal product as packaged for sale: 30 months

6.4 Special precautions for storage

This veterinary medicinal product does not require any special storage conditions. Any remaining tablet portion should be returned to the blister and given at the next administration.

6.5 Nature and composition of immediate packaging

OPA/Aluminium/PVC foil and Aluminium foil blister containing 10 tablets

Cardboard box of 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, or 250 tablets.

Not all pack sizes may be marketed.

6.6 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements.

7. MARKETING AUTHORISATION HOLDER

Ecuphar NV
Legeweg 157-i
8020 Oostkamp
Belgium

8. MARKETING AUTHORISATION NUMBER

Vm 32742/4015

9. DATE OF FIRST AUTHORISATION

29 October 2019

10. DATE OF REVISION OF THE TEXT

January 2022

Approved: 13/01/22

D. Austin